Apollomics Announces Presentation at the 2024 BIO International Convention
Apollomics Announces Presentation at the 2024 BIO International Convention
Management will be available for one-on-one meetings with registered attendees. To schedule a meeting with the Company's management at the convention, please submit a meeting request through the BIO One-on-One Partnering system or contact FOSTER CITY, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. ("Apollomics" or the "Company") (Nasdaq: APLM), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that the Company will present at the 2024 BIO International Convention being held June 3-6, 2024 in San Diego, California.
加利福尼亞州福斯特城，2024 年 5 月 29 日（GLOBE NEWSWIRE）— Apollomics Inc. （“Apollomics” 或 “公司”）（納斯達克股票代碼：APLM）是一家臨床階段的生物製藥公司，正在開發多種抗腫瘤候選藥物，以治療難以治療和耐藥的癌症。該公司今天宣佈，該公司將出席2024年6月3日至6日在加利福尼亞州聖地亞哥舉行的2024 BIO國際大會。
BIO International Convention (June 3-6, 2024)
BIO 國際大會（2024 年 6 月 3 日至 6 日）
Format: In-person
Location: San Diego, California
Presentation Date: Tuesday, June 4, 2024
Location: Theater 2 located in Hall A of the Exhibition Hall at the San Diego Convention Center
Presentation Time: 3:15 p.m.
Presenter: Sanjeev Redkar, PhD, President and Executive Director of Apollomics
格式：面對面
地點：加利福尼亞州聖地亞哥
演講日期：2024 年 6 月 4 日，星期二
地點：2號劇院位於聖地亞哥會議中心展覽廳A廳
演講時間：下午 3:15
主持人：桑傑夫·雷德卡，博士，Apollomics總裁兼執行董事
Management will be available for one-on-one meetings with registered attendees. To schedule a meeting with the Company's management at the convention, please submit a meeting request through the BIO One-on-One Partnering system or contact brandon.weiner@westwicke.com.
管理層將可以與註冊與會者進行一對一的會議。要安排在大會上與公司管理層會面，請通過BIO一對一合作系統提交會議請求或聯繫 brandon.weiner@westwicke.com。
About Apollomics Inc.
Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics currently has a pipeline of nine drug candidates across multiple programs, six of which are currently in the clinical stage of development. Apollomics' lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. For more information, please visit www.apollomicsinc.com.
Apollomics Inc. 是一家處於臨床階段的創新生物製藥公司，專注於腫瘤療法的發現和開發，有可能與其他治療方案相結合，利用免疫系統和靶向特定的分子途徑來抑制癌症。Apollomics目前有九種候選藥物在線，涵蓋多個項目，其中六種目前處於臨床開發階段。Apollomics的主要項目包括vebreltinib（APL-101），一種有效的選擇性c-Met抑制劑，用於治療非小細胞肺癌和其他具有c-Met變異的晚期腫瘤，以及uproleselan（APL-106），一種特定的E-Selectin拮抗劑，有可能與標準化療一起輔助使用來治療急性髓系白血病。欲了解更多信息，請訪問 www.apollomicsinc.com。
CONTACTS
Investor Relations
Peter Vozzo
ICR Westwicke
Peter.Vozzo@westwicke.com
+1-443-213-0505
聯繫人
投資者關係
彼得·沃佐
ICR Westwicke
Peter.Vozzo@westwicke.com
+1-443-213-0505
Media Relations
Sean Leous
ICR Westwicke
Sean.Leous@westwicke.com
+1-646-866-4012
媒體關係
肖恩·萊奧斯
ICR Westwicke
Sean.Leous@westwicke.com
+1-646-866-4012
譯文內容由第三人軟體翻譯。